Vogt-Koyanagi-Harada (VKH) syndrome is a rare autoimmune disease that affects melanin-containing tissues like the eyes, inner ears, skin, and brain. It is characterized by bilateral uveitis and can cause vision loss. The disease occurs in phases including prodromal, acute uveitic, convalescent, and recurrent. Treatment involves high-dose corticosteroids for at least 6 months to reduce inflammation and recurrence risk. Immunosuppressants may be needed for resistant cases. Prognosis depends on factors like early treatment, treatment duration, and presence of complications. Strict monitoring is needed due to risk of vision threatening complications.